>
Switch to:

ORIC Pharmaceuticals Interest Coverage

: No Debt (As of Jun. 2021)
View and export this data going back to 2020. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. ORIC Pharmaceuticals's Operating Income for the three months ended in Jun. 2021 was $-21.06 Mil. ORIC Pharmaceuticals's Interest Expense for the three months ended in Jun. 2021 was $0.00 Mil. ORIC Pharmaceuticals has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. ORIC Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for ORIC Pharmaceuticals's Interest Coverage or its related term are showing as below:

NAS:ORIC' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


NAS:ORIC's Interest Coverage is ranked higher than
98% of the 86 Companies
in the Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ORIC: No Debt )

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


ORIC Pharmaceuticals Interest Coverage Historical Data

The historical data trend for ORIC Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20
Interest Coverage
No Debt No Debt No Debt

ORIC Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Interest Coverage Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison

For the Biotechnology subindustry, ORIC Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ORIC Pharmaceuticals Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's Interest Coverage falls into.



ORIC Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt.


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ORIC Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2020 is calculated as

Here, for the fiscal year that ended in Dec. 2020, ORIC Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-49.34 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

ORIC Pharmaceuticals had no debt.

ORIC Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2021 is calculated as

Here, for the three months ended in Jun. 2021, ORIC Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-21.06 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

ORIC Pharmaceuticals had no debt.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


ORIC Pharmaceuticals  (NAS:ORIC) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


ORIC Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of ORIC Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


ORIC Pharmaceuticals Business Description

ORIC Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533.
Executives
Kunkel Lori Anne director C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Chacko Jacob director, officer: President and CEO C/O IGNYTA, INC. 11095 FLINTKOTE AVE., SUITE D SAN DIEGO CA 92121
Topspin Biotech Fund Ii, L.p. 10 percent owner 3 EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Lg Management, Llc 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Topspin Fund L.p. 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Heyman Richard A. director 5871 OBERLIN DRIVE, SUITE 150 SAN DIEGO CA 92121
Scheller Richard H director C/O GENENTECH INC 1 DNA WAY MS 49 SOUTH SAN FRANCISCO CA 94080-4990
Guthart Leo 10 percent owner C/O APTUR GROUP INC 475 W TERRA COTTA AVE STE E CRYSTAL LAKE IL 60014
Column Group Ii Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Goeddel David V 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Svennilson Peter director, 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Gordon Carl L director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Orbimed Capital Gp Vi Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022

ORIC Pharmaceuticals Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)